The sufferers of hemophilia B will soon have a new treatment option from Biogen. The drug company, which operates a huge manufacturing facility in RTP, on Friday received FDA approval for Alprolix and now will enter the $1 billion a year hemophilia market.
Biogen, which is based in Cambridge, Mass., reported the FDA decision late Friday.
Alrpolix combats the bleeding disorder based on DNA derived therapy.
Biogen describes the drug as the first significant advance in hemophilia treatment “in more than 17 years.”
“The FDA approval of Alprolix is a significant milestone for the hemophilia B community, and represents an important first step in our commitment to transform the care of people with hemophilia,” said George Scangos, chief executive officer of Biogen Idec. “Alprolix offers people with hemophilia B the ability to prevent or reduce bleeding episodes with prophylactic infusions starting at least a week apart.”
